POSC377 Twelve-Month Follow up of Ixekizumab in the Badbir Registry: Baseline Demographics, Drug Survival and Effectiveness in Biologic-Naïve Versus Biologic-Experienced Patients with Psoriasis
Abstract
Authors
S Zaheri J Hughes R McKenzie LB von Arx